Brian Nowosielski

This episode explores a specific generalization within pharmacy practice that leaders should actively avoid while simultaneously looking toward overcoming key hurdles affecting team members.

Through the lens of geographic and racial accessibility, researchers explore OTC naloxone sales and costs in North Carolina.

Pneumococcal aortitis is a rare but life-threatening aortic infection that highlights the concerning interplay between pneumococcal disease and cardiovascular disease risk and mortality.

Lani Bertrand, senior director of clinical marketing & thought leadership at Omnicell, discusses the consistent drivers of drug shortages in the US.

Researchers explore the serotypes, vaccination, and risk factors associated with pneumococcal disease mortality among in-hospital patients in Spain.

With its initial rollout beginning in 2026, the Medicare Drug Price Negotiation Program has caused significant strain on the cash flow of independent pharmacies.

With a growing prevalence of medication use across the US, researchers explore overall use of OTC and prescription drugs from June 2023 to April 2024.

With a key exemption under DSCSA expiring at the end of the year, Matt Sample from Cencora helps pharmacies understand the tools and processes they need now to best comply with the law.

Pharmacists are taking the lead to combat misinformation on measles and preserve the nation’s fragile elimination status.

Matt Sample, senior vice president of manufacturer, quality, and replenishment operations at Cencora, discusses DSCSA compliance hurdles, VRS tools, and a new push toward 12-digit NDCs.

Episode 8 explores the real-world evidence, clinical trial data, and overall application of finerenone for pharmacists and their patients.

Matt Sample from Cencora discusses current DSCSA developments on the rise for pharmacy businesses in 2026—namely small dispensers that have been under exemption.

The event will explore how community pharmacy leaders can improve profitability, business resilience, as well as PBM and reimbursement challenges.

With patients and pharmacists existing in new territories since the COVID-19 pandemic, at-home diagnostic testing has come a long way in improving the potential for convenient access to care.

Navitus Health Solutions conducted a survey of 2000 US adults who have been taking glucagon-like peptide-1 therapies for the past 2 years.

In part 2 of our conversation with CLIAwaived Inc CEO Tim Drapeau, we explored the future horizons in community pharmacy and how at-home testing is advancing the pharmacist’s role in health care.

In this episode, host Taylor Watterson, PharmD, PhD, welcomes Mohammad Al Numan, BS, MS, a 2025-27 University of Illinois Chicago/Takeda Fellow in Health Economics and Outcomes Research.

Upon approval, dupilumab becomes the first and only medication on the market to target adult and pediatric patients’ allergic fungal rhinosinusitis.

In a post-hoc analysis, researchers testnm the effects of tezepelumab against placebo among patients with severe uncontrolled asthma.

Tim Drapeau, CEO of CLIAwaived Inc, discusses his company’s new Test Yourself @ Home diagnostics kit and how it’s advancing the role of community pharmacy in real time.

Just before monumental PBM reform was signed into law, as well as a landmark settlement between the FTC and Express Scripts, the Department of Labor proposed its own set of PBM regulations.

Using the PRIME program’s framework, researchers explore a digital-health and pharmacy-based lifestyle intervention for improving risk factors among patients with prediabetes.

With the federal government continuing its reconsideration of vaccine guidelines in the US, Jeff Goad, PharmD, MPH, explains what it means for community pharmacies.

In a reversal of its refusal-to-file letter issued last week, the FDA decides to move forward with Moderna’s mRNA flu vaccine developments.

Amid common patient threats stemming from severe hypoglycemia, researchers explore how proactive pharmacist outreach can translate to safer prescribing regimens for patients with diabetes.

In this episode, Natalie DiPietro Mager, PharmD, PhD, MPH, chats with Laney Poye, the director of marketing and communications at the Preeclampsia Foundation.

Jeff Goad, PharmD, MPH, joins Drug Topics to discuss potential COVID-19 vaccine removal and what it could mean for the future of mRNA vaccine technology.

Positive phase 3 data from its KALOS and LOGOS trials show the efficacy and safety of Breztri compared with 2 additional therapies.

Through a mathematical model used to assess asthma dynamics, researchers explore how active smoking can impact disease outcomes.

Jeff Goad, PharmD, MPH, president of the NFID, discusses the nuances behind COVID-19 vaccine updates and what it can mean for patients and pharmacies alike.